X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs PANACEA BIOTECH - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA PANACEA BIOTECH GSK PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 61.5 -19.3 - View Chart
P/BV x 12.4 2.3 542.9% View Chart
Dividend Yield % 2.3 0.0 -  

Financials

 GSK PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
PANACEA BIOTECH
Mar-14
GSK PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs2,760149 1,856.1%   
Low Rs2,04082 2,478.7%   
Sales per share (Unadj.) Rs339.084.1 402.9%  
Earnings per share (Unadj.) Rs41.4-18.3 -226.2%  
Cash flow per share (Unadj.) Rs45.9-6.7 -685.2%  
Dividends per share (Unadj.) Rs35.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs242.983.7 290.2%  
Shares outstanding (eoy) m84.7061.25 138.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.11.4 515.7%   
Avg P/E ratio x57.9-6.3 -918.5%  
P/CF ratio (eoy) x52.3-17.2 -303.2%  
Price / Book Value ratio x9.91.4 716.1%  
Dividend payout %84.50-   
Avg Mkt Cap Rs m203,2807,074 2,873.5%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m5,2341,449 361.2%   
Avg. sales/employee Rs ThNM1,874.1-  
Avg. wages/employee Rs ThNM527.0-  
Avg. net profit/employee Rs ThNM-407.7-  
INCOME DATA
Net Sales Rs m28,7155,154 557.2%  
Other income Rs m545100 546.5%   
Total revenues Rs m29,2605,254 557.0%   
Gross profit Rs m5,059-766 -660.1%  
Depreciation Rs m380711 53.4%   
Interest Rs m21,503 0.1%   
Profit before tax Rs m5,222-2,881 -181.3%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m1781,771 10.1%   
Tax Rs m1,89217 11,261.9%   
Profit after tax Rs m3,508-1,121 -312.9%  
Gross profit margin %17.6-14.9 -118.5%  
Effective tax rate %36.2-0.6 -6,212.2%   
Net profit margin %12.2-21.8 -56.2%  
BALANCE SHEET DATA
Current assets Rs m21,8153,810 572.5%   
Current liabilities Rs m15,9998,365 191.2%   
Net working cap to sales %20.3-88.4 -22.9%  
Current ratio x1.40.5 299.4%  
Inventory Days Days64156 40.8%  
Debtors Days Days1967 27.8%  
Net fixed assets Rs m12,47514,480 86.2%   
Share capital Rs m84761 1,381.7%   
"Free" reserves Rs m19,726903 2,184.3%   
Net worth Rs m20,5735,127 401.3%   
Long term debt Rs m65,832 0.1%   
Total assets Rs m39,47519,433 203.1%  
Interest coverage x2,612.0-0.9 -284,997.2%   
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x0.70.3 274.3%   
Return on assets %8.92.0 452.7%  
Return on equity %17.1-21.9 -78.0%  
Return on capital %26.23.6 721.9%  
Exports to sales %024.5 0.0%   
Imports to sales %010.2 0.0%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs mNA525 0.0%   
Fx inflow Rs m5641,539 36.6%   
Fx outflow Rs m7,429942 788.6%   
Net fx Rs m-6,865597 -1,149.5%   
CASH FLOW
From Operations Rs m4,728599 789.1%  
From Investments Rs m-1,042-438 237.9%  
From Financial Activity Rs m-3,066-303 1,013.4%  
Net Cashflow Rs m620-141 -438.6%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 0.6 1,700.0%  
FIIs % 23.8 1.3 1,830.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 23.6 65.3%  
Shareholders   102,036 10,259 994.6%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   TORRENT PHARMA  ALKEM LABORATORIES  AJANTA PHARMA  PFIZER  ALEMBIC PHARMA  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Weak; FMCG Stocks Drag(12:30 pm)

Stock markets in India are trading in negative territory weighed by fast-moving consumer goods (FMCG) stocks.

Related Views on News

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Sep 26, 2018 01:47 PM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - ALKEM LABORATORIES COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS